| P2093 | author name string | Janice Gabrilove | |
| | Yan Li | |
| | Thomas J Kipps | |
| | James M Foran | |
| | Jennifer R Brown | |
| | Thomas P Miller | |
| | Daruka Mahadevan | |
| | Paul M Barr | |
| | Jeff P Sharman | |
| | Marshall T Schreeder | |
| | Shuo Ma | |
| | Jan A Burger | |
| | Brian T Hill | |
| | Kevin R Kelly | |
| | Wael A Harb | |
| | Daniel W Pierce | |
| | Jay Mei | |
| | Ada Azaryan | |
| | Evelyn Barnett | |
| | Jeffrey Marine | |
| | Monika Miranda | |
| | Pilar Nava-Parada | |
| | Xujie Yu | |
| P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
| | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 |
| | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 |
| | Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 |
| | Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia | Q36135185 |
| | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 |
| | B cell receptor signaling in chronic lymphocytic leukemia | Q38127513 |
| | "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''. | Q38140625 |
| | Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans | Q39412429 |
| | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Q40716705 |
| | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 |
| P433 | issue | 7 | |
| P921 | main subject | leukemia | Q29496 |
| | lymphocyte | Q715347 |
| P304 | page(s) | e295-8 | |
| P577 | publication date | 2016-05-05 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia | |
| P478 | volume | 101 | |